• 1
    Kubota N, Kanzawa F, Nishio K et al. Detection of topoisomerase I gene mutation in CPT-11 resistance lung cancer cell lines. Biochem Biophys Res Commun 1992; 188: 5717.
  • 2
    Ohashi N, Fujiwara Y, Yamaoka N, Katoh O, Satow Y, Yamakido M. No alteration in DNA topoisomerase I gene related to CPT-11 resistance in human lung cancer. Jpn J Cancer Res 1996; 87: 12807.
  • 3
    Iyer L, King CD, Whiington PF et al. Genetic predisposition of the metabolism of irinotecan (CPT-11). J Clin Invest 1998; 101: 84754.
  • 4
    Takahashi T, Fujiwara Y, Yamakido M, Katoh O, Watanabe H, Mackenzie PI. The role of glucuronidation in 7-ethyl-10-hydroxycamptothecin resistance in vitro. Jpn J Cancer Res 1997; 88: 121117.
  • 5
    Oguri T, Takahashi T, Miyazaki M et al. UGT1A10 is responsible for SN-38 glucuronidation and its expression in human lung cancers. Anticancer Res 2004; 24: 28936.
  • 6
    Koike K, Kawabe T, Tanaka T et al. A canalicular multispecific organ anion transporter (cMOAT) antisense cDNA enhances drug sensitivity in human hepatic cancer cells. Cancer Res 1997; 57: 54759.
  • 7
    Brabgi M, Litman T, Ciotti M et al. Camptothecin resistance: role of the ATP-binding cassette (ABC), mitoxantrone-resistance half-transporter (MXR), and potential for glucronidation in MXR-expression cells. Cancer Res 1999; 59: 598346.
  • 8
    Kawabata S, Oka M, Shiozawa K et al. Breast cancer resistance protein directly confers SN-38 resistance of lung cancer cells. Biochem Biophys ResCommun 2001; 280: 121623.
  • 9
    Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer. A meta-analysis using updated data on individual patients from 52 randomized clinical trials. BMJ 1995; 311: 899909.
  • 10
    Schiller JH, Harrington D, Belani CP et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346: 928.
  • 11
    Noda K, Nishiwaki Y, Kawahara M et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 2002; 346: 8591.
  • 12
    Negoro S, Masuda N, Takada Y et al. Randomised phase III trial of irinotecan combined with cisplatin for advanced non-small-cell lung cancer. Br J Cancer 2003; 88: 33541.
  • 13
    Ishii M, Iwahana M, Mitsui I et al. Growth inhibitory effect of a new camptothecin analog, DX-8951f, on various drug-resistant sublines including BCRP-mediated camptothecin derivative-resistant variants derived from the human lung cancer cell line PC-6. Anticancer Drugs 2002; 11: 35362.
  • 14
    Hirata S, Katoh O, Oguri T, Watanabe H, Yajin K. Expression of drug resistance-related genes in head and neck squamous cell carcinomas and normal mucosa. Jpn J Cancer Res 2000; 91: 8490.
  • 15
    Kawabata S, Oka M, Soda H et al. Expression and functional analyses of breast cancer resistance protein in lung cancer. Clin Cancer Res 2003; 9: 30527.
  • 16
    Wierdl M, Wall A, Morton CL et al. Carboxylesterase-mediated sensitization of human tumor cells to CPT-11 cannot override ABCG2-mediated drug resistance. Mol Pharmacol 2003; 64: 27988.
  • 17
    Haimeur A, Conseil G, Deeley RG, Cole SP. The MRP-related and BCRP/ABCG2 multidrug resistance proteins: biology, substrate specificity and regulation. Curr Drug Metab 2004; 5: 2153.
  • 18
    Chu XY, Kato Y, Ueda K et al. Biliary excretion mechanism of CPT-11 and its metabolites in humans: involvement of primary active transporters. Cancer Res 1998; 58: 513743.
  • 19
    Nakatomi K, Yoshikawa M, Oka M et al. Transport of 7-ethyl-10-hydroxycamptothecin (SN-38) by breast cancer resistance protein ABCG2 in human lung cancer cells. Biochem Biophys Res Commun 2001; 288: 82732.
  • 20
    Volk EL, Rohde K, Rhee M et al. Methotrexate cross-resistance in a mitoxantrone-selected multidrug-resistant MCF7 breast cancer cell line is attributable to enhanced energy-dependent drug efflux. Cancer Res 2000; 60: 351421.
  • 21
    Candeil L, Gourdier I, Peyron D et al. ABCG2 overexpression in colon cancer cells resistant to SN38 and in irinotecan-treated metastases. Int J Cancer 2004; 109: 84885.
  • 22
    Wang CY, Cusack JC Jr, Liu R, Baldwin AS Jr. Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-κB. Nat Med 1999; 5: 41217.
  • 23
    Faneyte IF, Kristel PM, Maliepaard M et al. Expression of the breast cancer resistance protein in breast cancer. Clin Cancer Res 2002; 8: 106874.
  • 24
    Doyle LA, Ross DD. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene 2003; 22: 734058.
  • 25
    Imai Y, Tsukahara S, Asada S, Sugimoto Y. Phytoestrogens/flavonoids reverse breast cancer resistance protein/ABCG2-mediated multidrug resistance. Cancer Res 2004; 64: 434652.
  • 26
    Nakamura Y, Oka M, Soda H et al. Gefitinib (“Iressa”, ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance. Cancer Res 2005; 65: 154154.
  • 27
    Maliepaard M, Scheffer GL, Faneyte IF et al. Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res 2001; 61: 345864.